Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
NCT05030428Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- May 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 50
01
Overview
A Phase 3 trial of inclisiran in atherosclerotic cardiovascular disease (ASCVD), sponsored by Novartis. Started Nov 2021; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05030428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030428.